Literature DB >> 36262495

A Chronic Obstructive Pulmonary Disease Exacerbation Following the Administration of a COVID 19-Booster Vaccine: A Case Report.

William Gatenby1, Gifty Dominah2, Amrit Paudel3, Nahar Saleh3.   

Abstract

We present a case of a patient who presented to the emergency department with symptoms suggestive of a chronic obstructive pulmonary disease (COPD) exacerbation one day after receiving the BNT162b2 COVID-19 booster vaccine. Laboratory studies indicated she was in a state of inflammation, but not infection. Other potential triggers, including cardiac and viral etiologies, were ruled out. To our knowledge, this is the first documented case of a COPD exacerbation following the administration of the BNT162b2 COVID-19 vaccine.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  BNT162b2 mRNA Covid-19 vaccine; COVID-19; COVID-19 vaccine; Chronic obstructive pulmonary disease; Internal medicine; Pulmonary disease

Year:  2022        PMID: 36262495      PMCID: PMC9529658          DOI: 10.55729/2000-9666.1107

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


  4 in total

1.  The Johnson & Johnson Vaccine for COVID-19.

Authors:  Edward H Livingston; Preeti N Malani; C Buddy Creech
Journal:  JAMA       Date:  2021-04-20       Impact factor: 56.272

2.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

3.  18F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.

Authors:  Julie Steinberg; Alex Thomas; Amir Iravani
Journal:  Lancet       Date:  2021-03-08       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.